Shandong Lukang Pharmaceutical Co Ltd (600789) — Capital Reinvestment Ratio
Shandong Lukang Pharmaceutical Co Ltd (600789) has a Capital Reinvestment Ratio of 0.31x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥285.47 Million) in capital expenditures (CN¥88.93 Million). See Shandong Lukang Pharmaceutical Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shandong Lukang Pharmaceutical Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Shandong Lukang Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 28 annual periods. Check 600789 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Shandong Lukang Pharmaceutical Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Shandong Lukang Pharmaceutical Co Ltd from 1998 to 2025. For live market cap and broader valuation context, see Shandong Lukang Pharmaceutical Co Ltd (600789) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | CN¥698.17 Million | CN¥338.86 Million | ▼ -30.0% |
| 2024 | 0.69x | CN¥402.82 Million | CN¥279.18 Million | ▲ +23.9% |
| 2023 | 0.56x | CN¥604.01 Million | CN¥337.91 Million | ▼ -42.0% |
| 2022 | 0.96x | CN¥444.38 Million | CN¥428.36 Million | ▼ -70.4% |
| 2021 | 3.26x | CN¥149.33 Million | CN¥486.75 Million | ▲ +8.7% |
| 2020 | 3.00x | CN¥234.55 Million | CN¥703.12 Million | ▲ +30.9% |
| 2019 | 2.29x | CN¥361.87 Million | CN¥828.61 Million | ▼ -6.0% |
| 2018 | 2.44x | CN¥351.09 Million | CN¥855.24 Million | ▼ -14.0% |
| 2017 | 2.83x | CN¥275.51 Million | CN¥780.71 Million | ▲ +125.9% |
| 2016 | 1.25x | CN¥296.23 Million | CN¥371.51 Million | ▼ -40.3% |
| 2015 | 2.10x | CN¥78.39 Million | CN¥164.54 Million | ▲ +93.2% |
| 2014 | 1.09x | CN¥108.56 Million | CN¥117.94 Million | ▲ +21.0% |
| 2013 | 0.90x | CN¥256.50 Million | CN¥230.35 Million | ▼ -63.6% |
| 2012 | 2.47x | CN¥115.20 Million | CN¥284.40 Million | ▼ -29.0% |
| 2011 | 3.48x | CN¥123.28 Million | CN¥428.82 Million | ▲ +269.6% |
| 2010 | 0.94x | CN¥308.88 Million | CN¥290.69 Million | ▲ +169.9% |
| 2009 | 0.35x | CN¥199.49 Million | CN¥69.57 Million | ▼ -4.7% |
| 2008 | 0.37x | CN¥209.39 Million | CN¥76.58 Million | ▲ +116.0% |
| 2007 | 0.17x | CN¥137.30 Million | CN¥23.25 Million | ▼ -56.9% |
| 2006 | 0.39x | CN¥56.24 Million | CN¥22.12 Million | ▲ +3.7% |
| 2005 | 0.38x | CN¥161.64 Million | CN¥61.27 Million | ▼ -82.0% |
| 2004 | 2.10x | CN¥63.24 Million | CN¥133.10 Million | ▲ +96.6% |
| 2003 | 1.07x | CN¥167.42 Million | CN¥179.25 Million | ▲ +69.0% |
| 2002 | 0.63x | CN¥315.59 Million | CN¥199.94 Million | ▼ -15.8% |
| 2001 | 0.75x | CN¥270.43 Million | CN¥203.50 Million | ▼ -93.3% |
| 2000 | 11.21x | CN¥22.36 Million | CN¥250.64 Million | ▲ +312.0% |
| 1999 | 2.72x | CN¥35.12 Million | CN¥95.56 Million | ▼ -20.0% |
| 1998 | 3.40x | CN¥46.18 Million | CN¥156.96 Million | — |